FdaApplication
NDA 212194
Identifiers
- fda_app_no: NDA212194
Properties
| Property | Value |
|---|---|
| applicant_name | ALNYLAM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2019-11-20 |
Revenue by product
GIVLAARI
| Period | Revenue |
|---|---|
| Q2 2026 | $89.8M |
| Q1 2026 | $74.4M |
| Q3 2025 | $73.9M |
| Q2 2025 | $80.8M |
| Q1 2025 | $67.0M |
| Q4 2024 | $64.6M |
| Q3 2024 | $71.0M |
| Q2 2024 | $62.1M |
| Q1 2024 | $58.1M |
| Q4 2023 | $59.3M |
| Q3 2023 | $54.1M |
| Q2 2023 | $57.9M |
| Q1 2023 | $47.9M |
| Q4 2022 | $47.1M |
| Q3 2022 | $45.7M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| GIVLAARI | GIVOSIRAN SODIUM | EQ 189MG BASE/ML (EQ 189MG BASE/ML) | SOLUTION;SUBCUTANEOUS |
1 product